Your new post is loading...
A combination of old drugs is not inferior to biologics for rheumatoid arthritis • Tumor necrosis factor inhibitors are safe and effective therapies for patients with rheumatoid arthritis resistant to methotrexate and other disease modifying drugs,...
Via Krishan Maggon
The BMJ Today reports the results of an open label pragmatic trial—the TACIT trial—that compared the impact on disability at 12 months of a TNF based strategy (as recommended by the National Institute for Health and Care Excellence) versus a combined disease modifying drug strategy, which includes methotrexate. In this study, the combination of older drugs was non-inferior to the biologic agents.
In a related editorial, Pierre Miossec concludes that the TACIT trial “gives fresh hope to more patients around the world that they can achieve equal or better disease control with combinations of established, low cost, and easy to produce alternatives [to the more expensive newer biologics].”